Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial
Background: In order to fulfil the requirements of the national immunization program and sustain the production capacity of the monovalent Hepatitis B vaccine, this study aimed to assess the safety and immunogenicity of the recombinant Hepatitis B Vaccine (Bio Farma) using the new Hepatitis B bulk....
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Padjadjaran
2023-12-01
|
| Series: | Althea Medical Journal |
| Subjects: | |
| Online Access: | https://journal.fk.unpad.ac.id/index.php/amj/article/view/3279 |
| _version_ | 1797219473796628480 |
|---|---|
| author | Eddy Fadlyana Rodman Tarigan Kusnandi Rusmil Rini Mulia Sari Cissy B Kartasmita Behesti Zahra Mardiah Muhammad Gilang Dwi Putra |
| author_facet | Eddy Fadlyana Rodman Tarigan Kusnandi Rusmil Rini Mulia Sari Cissy B Kartasmita Behesti Zahra Mardiah Muhammad Gilang Dwi Putra |
| author_sort | Eddy Fadlyana |
| collection | DOAJ |
| description | Background: In order to fulfil the requirements of the national immunization program and sustain the production capacity of the monovalent Hepatitis B vaccine, this study aimed to assess the safety and immunogenicity of the recombinant Hepatitis B Vaccine (Bio Farma) using the new Hepatitis B bulk.
Methods: This study was an experimental, randomized, double-blinded, and controlled Phase I clinical trial, with 100 healthy subjects divided into 50 adults and 50 adolescents. Subjects were randomly assigned to receive either the Bio Farma registered Recombinant Hepatitis B Vaccine (group A) or a new source of Hepatitis B bulk (group B). Subjects received one or three doses of vaccine, depending on the baseline anti-Hbs titer. Subjects were given diary cards to record solicited and unsolicited adverse events for 28 days following vaccination. Vaccine immunogenicity was assessed by measuring the level of HBsAg antibody titer elevation.
Results: No serious adverse events were reported during clinical trials. The frequencies of adverse events were not significantly different between the two vaccine-randomized groups. The most immediately observed local reaction was local pain, reported by 35.7–42.8% of adults and 24.0–26.3% of adolescents, without any systemic reactions. Seroconversion in adults in group B reached 100% and 78.5% in group A, meanwhile in adolescent subjects in both groups it reached 100%. A substantial increase in geometric mean titer (GMT) was observed in the majority of subjects after immunization.
Conclusion: Recombinant Hepatitis B Vaccine with a new source of HBsAg B bulk is safe, well tolerated, and highly immunogenic. |
| first_indexed | 2024-04-24T12:34:13Z |
| format | Article |
| id | doaj.art-9a2f048cea434263b878ff35ab60d2db |
| institution | Directory Open Access Journal |
| issn | 2337-4330 |
| language | English |
| last_indexed | 2024-04-24T12:34:13Z |
| publishDate | 2023-12-01 |
| publisher | Universitas Padjadjaran |
| record_format | Article |
| series | Althea Medical Journal |
| spelling | doaj.art-9a2f048cea434263b878ff35ab60d2db2024-04-07T14:07:19ZengUniversitas PadjadjaranAlthea Medical Journal2337-43302023-12-0110410.15850/amj.v10n4.32791658Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical TrialEddy Fadlyana0Rodman Tarigan1Kusnandi Rusmil2Rini Mulia Sari3Cissy B Kartasmita4Behesti Zahra Mardiah5Muhammad Gilang Dwi Putra6Department of Child Health Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Child Health Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Child Health Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungPT Bio Farma, Bandung, West Java, IndonesiaDepartment of Child Health Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Child Health Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Child Health Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungBackground: In order to fulfil the requirements of the national immunization program and sustain the production capacity of the monovalent Hepatitis B vaccine, this study aimed to assess the safety and immunogenicity of the recombinant Hepatitis B Vaccine (Bio Farma) using the new Hepatitis B bulk. Methods: This study was an experimental, randomized, double-blinded, and controlled Phase I clinical trial, with 100 healthy subjects divided into 50 adults and 50 adolescents. Subjects were randomly assigned to receive either the Bio Farma registered Recombinant Hepatitis B Vaccine (group A) or a new source of Hepatitis B bulk (group B). Subjects received one or three doses of vaccine, depending on the baseline anti-Hbs titer. Subjects were given diary cards to record solicited and unsolicited adverse events for 28 days following vaccination. Vaccine immunogenicity was assessed by measuring the level of HBsAg antibody titer elevation. Results: No serious adverse events were reported during clinical trials. The frequencies of adverse events were not significantly different between the two vaccine-randomized groups. The most immediately observed local reaction was local pain, reported by 35.7–42.8% of adults and 24.0–26.3% of adolescents, without any systemic reactions. Seroconversion in adults in group B reached 100% and 78.5% in group A, meanwhile in adolescent subjects in both groups it reached 100%. A substantial increase in geometric mean titer (GMT) was observed in the majority of subjects after immunization. Conclusion: Recombinant Hepatitis B Vaccine with a new source of HBsAg B bulk is safe, well tolerated, and highly immunogenic.https://journal.fk.unpad.ac.id/index.php/amj/article/view/3279adultsadolescentsimmunogenicitysafetyrecombinant hepatitis b vaccine |
| spellingShingle | Eddy Fadlyana Rodman Tarigan Kusnandi Rusmil Rini Mulia Sari Cissy B Kartasmita Behesti Zahra Mardiah Muhammad Gilang Dwi Putra Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial Althea Medical Journal adults adolescents immunogenicity safety recombinant hepatitis b vaccine |
| title | Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial |
| title_full | Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial |
| title_fullStr | Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial |
| title_full_unstemmed | Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial |
| title_short | Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial |
| title_sort | safety and preliminary immunogenicity of recombinant hepatitis b bio farma vaccine in adults and children a phase 1 clinical trial |
| topic | adults adolescents immunogenicity safety recombinant hepatitis b vaccine |
| url | https://journal.fk.unpad.ac.id/index.php/amj/article/view/3279 |
| work_keys_str_mv | AT eddyfadlyana safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial AT rodmantarigan safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial AT kusnandirusmil safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial AT rinimuliasari safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial AT cissybkartasmita safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial AT behestizahramardiah safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial AT muhammadgilangdwiputra safetyandpreliminaryimmunogenicityofrecombinanthepatitisbbiofarmavaccineinadultsandchildrenaphase1clinicaltrial |